BCL2 and cervical cancer: However, increasing drug efflux, elevated intracellular glutathione levels (detoxification), inhibition of apoptosis, and alterations in the expression of BCL-2 family members are the most consistent characteristics that contribute to the CIS-R phenotype in cervical cancer (5, 6).